Document is current
Any future updates will be listed below
-
Authors
Ebrahimi, Hedyeh https://orcid.org/0000-0003-3647-7356
Dizman, Nazli
Meza, Luis
Malhotra, Jasnoor
Li, Xiaochen
Dorff, Tanya https://orcid.org/0000-0001-5990-298X
Frankel, Paul
Llamas-Quitiquit, Marian
Hsu, Joann
Zengin, Zeynep B. https://orcid.org/0000-0002-2751-5915
Alcantara, Marice
Castro, Daniela https://orcid.org/0000-0002-5423-9821
Mercier, Benjamin
Chawla, Neal
Chehrazi-Raffle, Alex
Barragan-Carrillo, Regina
Jaime-Casas, Salvador https://orcid.org/0009-0009-4334-1300
Govindarajan, Ameish
Gillece, John
Trent, Jeffrey https://orcid.org/0000-0003-0183-4202
Lee, Peter P. https://orcid.org/0000-0002-2660-4377
Parks, Thomas P.
Takahashi, Motomichi https://orcid.org/0000-0003-4773-5904
Hayashi, Atsushi https://orcid.org/0000-0003-4060-2383
Kortylewski, Marcin https://orcid.org/0000-0002-6003-1816
Caporaso, J. Gregory
Lee, Keehoon
Tripathi, Abhishek https://orcid.org/0000-0003-4466-1874
Pal, Sumanta K. https://orcid.org/0000-0002-1712-0848
- License Information
-
More Information
Article History
Received: 4 February 2024
Accepted: 23 May 2024
First Online: 28 June 2024
Competing interests
: N.D. reports an immediate family member holding stocks and ownership in several pharmaceutical companies unrelated to this work. T.D. has received consulting fees from AstraZeneca, Bayer, Janssen and Sanofi. A.C.-R. has received research funding from Exelixis and has received consulting fees from Exelixis, AVEO and Tempus Labs. P.P.L. is a board member of Osel, Inc. and an inventor on US Patent Application 2023/0149479 (Compositions and methods comprising <i>C</i>. <i>butyricum</i> for the treatment of cancer). T.P.P. is an employee of Osel, Inc. M.T. and A.H. have received personal fees from Miyarisan Pharmaceutical Co., Ltd. J.G.C. is the chief science officer of Cymis Benefit Corporation, unrelated to this work. A.T. has received consulting fees from Deka Biosciences, Aadi Biosciences, Seattle Genetics/Astellas, Exelixis, Bayer and Gilead Sciences and research funding from Corvus Pharmaceuticals, EMD Serono and Aravive, Inc. S.K.P. has received travel support from Ipsen, CRISPR and Exelixis. The other authors declare no competing interests.
